Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryThirty firms win roles in revamped £820m government legal panel – with three new appointments‘There’s definitely competition around rates’ – Clifford Chance and Linklaters match Cravath bonuses for US associatesRevolving Doors: Proskauer boosts London finance team as Paul Weiss picks up another Kirkland partner‘For us, it all came together’ – how Proskauer built a London high yield offering in 12 monthsSlaughters, Gibson Dunn lead on Daily Mail’s £500m Telegraph Media Group acquisitionCohen & Gresser follows McDermott in eyeing up external investmentDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture